Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Withdrawn × gilteritinib × Clear all

Phase

Phase 1 2 Phase 1/2 1

Status

Terminated 3 Recruiting 3 Completed 3 Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1 Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 21 pembrolizumab 18 Nivolumab 14 Fluorouracil 14 Cisplatin 14 Leucovorin 12 Capecitabine 12 Bevacizumab 12 Oxaliplatin 11 Carboplatin 11 Lenalidomide 10 avelumab 9 Rituximab 9 Dexamethasone 9 fludarabine 8 Taxes 8 Radiosurgery 8 Gemcitabine 8 Radiotherapy 7 Irinotecan 7 Ipilimumab 7 Docetaxel 7 Azacitidine 7 ALT-803 7 venetoclax 6 Omacor 6 Interleukin-2 6 Etoposide 6 Cetuximab 6 fludarabine phosphate 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05279859 2022-06-15

HERKULES-4

Erasca, Inc.

Phase 1/2 Withdrawn

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡